Featured Image
Why is it important?
No studies have evaluated the use of sorafenib with the direct‐acting antiviral ombitasvir/paritaprevir/ritonavir and dasabuvir (OBV/PTV/r+DSV).
Read the Original
This page is a summary of: Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice, Journal of Clinical Pharmacy and Therapeutics, June 2018, Wiley,
DOI: 10.1111/jcpt.12727.
You can read the full text:
Contributors
The following have contributed to this page
